Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemias

Hematology/Oncology Clinics of North America

Volumn 18, Issue 6 SPEC.ISS., 2004, Pages 1355-1377

  Kwiatkowski, Janet L ^a,b   Cohen, Alan R ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON CHELATING AGENT;

ABDOMINAL PAIN; AGRANULOCYTOSIS; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; BETA THALASSEMIA; BONE DISEASE; CLINICAL TRIAL; COLOR VISION DEFECT; DIARRHEA; DRUG ERUPTION; DRUG HYPERSENSITIVITY; ERYTHEMA; ERYTHROCYTE TRANSFUSION; EYE DISEASE; EYE TOXICITY; FERRITIN BLOOD LEVEL; FIBROSING ALVEOLITIS; GASTROINTESTINAL DISEASE; GROWTH RETARDATION; HEADACHE; HEARING DISORDER; HEART DISEASE; HUMAN; HYPERSPLENISM; HYPOXEMIA; INJECTION PAIN; IRON CHELATION; IRON OVERLOAD; LIVER BIOPSY; LUNG DISEASE; LUNG TOXICITY; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; NIGHT BLINDNESS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OTOTOXICITY; PAIN; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RESPIRATORY DISTRESS; REVIEW; RICKETS; RISK ASSESSMENT; RISK FACTOR; SICKLE CELL ANEMIA; SIDE EFFECT; SKIN INDURATION; THALASSEMIA; TRANSFUSION; URINE COLOR; VALGUS KNEE; VISUAL ACUITY; VOMITING;

EID: 7044227861     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2004.06.019     Document Type: Review

References (108)

1. D. Powars, B. Wilson, C. Imbus, C. Pegelow, and J. Allen The natural history of stroke in sickle cell disease Am J Med 65 3 1978 461 471
2. C.H. Pegelow, R.J. Adams, V. McKie, M. Abboud, B. Berman, and S.T. Miller Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions J Pediatr 126 6 1995 896 899
3. R.J. Adams, V.C. McKie, L. Hsu, B. Files, E. Vichinsky, and C. Pegelow Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography N Engl J Med 339 1 1998 5 11
4. C.H. Pegelow, E.A. Macklin, F.G. Moser, W.C. Wang, J.A. Bello, and S.T. Miller Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease Blood 99 8 2002 3014 3018
5. F. Bernaudin, S. Verlhac, F. Freard, F. Roudot-Thoraval, M. Benkerrou, and I. Thuret Multicenter prospective study of children with sickle cell disease: radiographic and psychometric correlation J Child Neurol 15 5 2000 333 343
6. F.D. Armstrong, R.J. Thompson Jr, W. Wang, R. Zimmerman, C.H. Pegelow, and S. Miller Cognitive functioning and brain magnetic resonance imaging in children with sickle cell disease Pediatrics 97 6 pt 1 1996 864 870
7. S.T. Miller, E.A. Macklin, C.H. Pegelow, T.R. Kinney, L.A. Sleeper, and J.A. Bello Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease J Pediatr 139 3 2001 385 390
8. E. Vichinsky Consensus document for transfusion-related iron overload Sem Hematol 38 Suppl 1 2001 2 4
9. S.K. Ballas Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease Sem Hematol 38 Suppl 1 2001 30 36
10. W. Breuer, C. Hershko, and Z.I. Cabantchik The importance of non-transferrin bound iron in disorders of iron metabolism Transfus Sci 23 3 2000 185 192
11. M.G. Zurlo, P. De Stefano, C. Borgna-Pignatti, A. Di Palma, A. Piga, and C. Melevendi Survival and causes of death in thalassaemia major Lancet 2 8653 1989 27 30
12. G. Jean, S. Terzoli, R. Mauri, L. Borghetti, A. Di Palma, and A. Piga Cirrhosis associated with multiple transfusions in thalassaemia Arch Dis Child 59 1 1984 67 70
13. M.N. Lassman, M. Genel, J.K. Wise, R. Hendler, and P. Felig Carbohydrate homoeostasis and pancreatic islet cell function in thalassemia Ann Intern Med 80 1 1974 65 69
14. C. Borgna-Pignatti, P. De Stefano, L. Zonta, C. Vullo, V. De Sanctis, and C. Melevendi Growth and sexual maturation in thalassemia major J Pediatr 106 1 1985 150 155
15. Harmatz P, Butensky E, Fung E, Louie L, Theil E, Ferrell L. Organ injury in chronically transfused patients with beta thalassemia or sickle cell disease. Presented at the 30th Anniversary Meeting of the National Sickle Cell Disease Program. Washington DC: September 17-21, 2002.
16. P. Harmatz, E. Butensky, K. Quirolo, R. Williams, L. Ferrell, and T. Moyer Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy Blood 96 1 2000 76 79
17. J.C. Wood, J.M. Tyszka, S. Carson, M.D. Nelson, and T.D. Coates Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease Blood 103 5 2004 1934 1936
18. Fung EB, Harmatz PR, Madden J, Vichinsky E. Group M-CSoIOS: organ dysfunction in iron overloaded patients with beta-thalassemia or sickle cell disease. Presented at the 27th Annual Meeting of the National Sickle Cell Disease Program. Los Angeles: April 18-21, 2004.
19. P.T. Telfer, E. Prestcott, S. Holden, M. Walker, A.V. Hoffbrand, and B. Wonke Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major Br J Haematol 110 4 2000 971 977
20. G.M. Brittenham, A.R. Cohen, C.E. McLaren, M.B. Martin, P.M. Griffith, and A.W. Nienhuis Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major Am J Hematol 42 1 1993 81 85
21. N.F. Olivieri, D.G. Nathan, J.H. MacMillan, A.S. Wayne, P.P. Liu, and A. McGee Survival in medically treated patients with homozygous beta thalassemia N Engl J Med 331 9 1994 574 578
22. A. Brownell, S. Lowson, and M. Brozovic Serum ferritin concentration in sickle crisis J Clin Pathol 39 3 1986 253 255
23. M.A. Hussain, L.R. Davis, M. Laulicht, and A.V. Hoffbrand Value of serum ferritin estimation in sickle cell anaemia Arch Dis Child 53 4 1978 319 321
24. B. Files, D. Brambilla, A. Kutlar, S. Miller, E. Vichinsky, and W. Wang Longitudinal changes in ferritin during chronic transfusion: a report from the Stroke Prevention Trial in Sickle Cell Anemia (STOP) J Pediatr Hematol Oncol 24 4 2002 284 290
25. M. Barry, and S. Sherlock Measurement of liver-iron concentration in needle-biopsy specimens Lancet 1 7690 1971 100 103
26. E. Angelucci, G.M. Brittenham, C.E. McLaren, M. Ripalti, D. Baronciani, and C. Giardini Hepatic iron concentration and total body iron stores in thalassemia major N Engl J Med 343 5 2000 327 331
27. J.P. Villeneuve, M. Bilodeau, R. Lepage, J. Cote, and M. Lefebvre Variability in hepatic iron concentration measurement from needle-biopsy specimens J Hepatol 25 2 1996 172 177
28. L.J. Anderson, S. Holden, B. Davis, E. Prescott, C.C. Charrier, and N.H. Bunce Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload Eur Heart J 22 23 2001 2171 2179
29. G.M. Brittenham, D.E. Farrell, J.W. Harris, E.S. Feldman, E.H. Danish, and W.A. Muir Magnetic-susceptibility measurement of human iron stores N Engl J Med 307 27 1982 1671 1675
30. Z.J. Wang, J.C. Haselgrove, M.B. Martin, A.M. Hubberd, S. Li, and K. Loomes Evaluation of iron overload by single voxel MRS measurement of liver T2 J Mag Reson Imag 15 4 2002 395 400
31. M. Westwood, L.J. Anderson, D.N. Firmin, P.D. Gatehouse, C.C. Charrier, and B. Wonke A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload J Magn Reson Imag 18 1 2003 33 39
32. M.I. Argyropoulou, Z. Metafratzi, D.N. Kiortsis, S. Bitsis, A. Tsatsoulis, and S. Efremidis T2 relaxation rate as an index of pituitary iron overload in patients with beta-thalassemia major AJR 175 6 2000 1567 1569
33. G.C. Ooi, P.L. Khong, G.C. Chan, K.L. Chan, W. Lam, and I. Ng Magnetic resonance screening of iron status in transfusion-dependent beta-thalassaemia patients Br J Haematol 124 3 2004 385 390
34. G.M. Brittenham, and D.G. Badman Noninvasive measurement of iron: report of an NIDDK workshop Blood 101 1 2003 15 19
35. P. Lee, N. Mohammed, L. Marshall, R.D. Abeysinghe, R.C. Hider, and J.B. Porter Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients Drug Metab Disp 21 4 1993 640 644
36. M.J. Pippard, E.A. Letsky, S.T. Callender, and D.J. Weatherall Prevention of iron loading in transfusion-dependent thalassaemia Lancet 1 8075 1978 1178 1181
37. A.W. Nienhuis Vitamin C and iron N Engl J Med 304 3 1981 170 171
38. M. Barry, D.M. Flynn, E.A. Letsky, and R.A. Risdon Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress BMJ 2 909 1974 16 20
39. A.R. Cohen, M. Martin, and E. Schwartz Depletion of excessive liver iron stores with desferrioxamine Br J Haematol 58 1984 369 373
40. L. Wolfe, N. Olivieri, D. Sallan, S. Colan, V. Rose, and R. Propper Prevention of cardiac disease by sucutaneous deferoxamine in patients with thalassemia major N Engl J Med 312 25 1985 1600 1603
41. P. Wacker, D.S. Halperin, D. Balmer-Ruedin, I. Oberhansli, and M. Wyss Regression of cardiac insufficiency after ambulatory intravenous deferoxamine in thalassemia major Chest 103 4 1993 1276 1278
42. B.A. Davis, and J.B. Porter Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia Blood 95 4 2000 1229 1236
43. M.A. Engle, M. Erlandson, and C.H. Smith Late cardiac complications of chronic, severe refractory anemia and hemochromatosis Circulation 30 1964 698 705
44. G.M. Brittenham, P.M. Griffith, A.W. Nienhuis, C.E. McLaren, N.S. Young, and E.E. Tucker Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major N Engl J Med 331 9 1994 567 573
45. A.R. Cohen, and E. Schwartz Excretion of iron in response to deferoxamine in sickle cell anemia J Pediatr 92 4 1978 659 662
46. A. Cohen, and E. Schwartz Iron chelation therapy in sickle cell anemia Am J Hematol 7 1 1979 69 76
47. N.F. Olivieri, J.R. Buncic, E. Chew, T. Gallant, R.V. Harrison, and N. Keenan Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions N Engl J Med 314 14 1986 869 873
48. G.B. Arden, B. Wonke, C. Kennedy, and E.R. Huehns Ocular changes in patients undergoing long term desferrioxamine treatment Br J Ophthal 68 12 1984 873 877
49. J.B. Porter, M.S. Jaswon, E.R. Huehns, C.A. East, and J.W. Hazell Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage Br J Haematol 73 3 1989 403 409
50. V. De Sanctis, A. Pinamonti, A. DiPalma, M. Sprocati, G. Atti, and M.R. Gamberini Growth and development in thalassamia major patients with severe bone lesions due to desferrioxamine Eur J Pediatr 155 1996 368 372
51. S. De Virgiliis, M. Congia, F. Frau, F. Argiolu, G. Diana, and F. Cucca Deferoxamine-induced growth retardation in patients with thalassemia major J Pediatr 113 4 1988 661 669
52. M.H. Freedman, D. Grisaru, N. Olivieri, I. MacLusky, and P.S. Thorner Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions Am J Dis Child 144 5 1990 565 569
53. M.B. Leonard, B.S. Zemel, D.A. Kawchak, K. Ohene-Frempong, and V.A. Stallings Plasma zinc status, growth, and maturation in children with sickle cell disease J Pediatr 132 3 Pt 1 1998 467 471
54. C.C. Silliman, V.M. Peterson, D.L. Mellman, D.J. Dixon, K.M. Hambidge, and P.A. Lane Iron chelation by deferoxamine in sickle cell patients with severe tranfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship J Lab Clin Med 122 1 1993 48 54
55. B. Modell, M. Khan, and M. Darlison Survival in beta thalassaemia-major in the U. K.: data from the UK Thalassaemia Register Lancet 355 2000 2051 2052
56. C. Borgna-Pignatti, S. Rugolotto, P. DeStefano, A. Piga, F. DiGregorio, and M.R. Gamberini Survival and disease complications in thalassemia major Ann N Y Acad Sci 850 1998 227 231
57. V. Gabutti, and A. Piga Results of long-term iron chelating therapy Acta Haematol 95 1 1996 26 36
58. A.R. Cohen, J. Mizanin, and E. Schwartz Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy J Pediatr 115 1 1989 151 155
59. M. Franchini, G. Gandini, M. de Gironcoli, A. Vassanelli, C. Borgna-Pignatti, and G. Aprili Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload Blood 95 9 2000 2776 2779
60. P. Harmatz, R.W. Grady, E. Vichinsky, P.J. Giardina, M. Jeng, and J. Madden A phase 1b study of the safety, pharmacokinetics, acute tolerability, and efficacy of ascending single doses of 40SD02 (CHF5140, GS 460) in iron-loaded patients Blood 102 11 2003 121a
61. A. Araujo, M. Kosaryan, A. MacDowell, D. Wickens, S. Puri, and B. Wonke A novel delivery system for continuous deferrioxamine infusion in transfusional iron overload Br J Haematol 93 4 1996 835 837
62. A.V. Hoffbrand, F. Al-Refaie, B. Davis, N. Siritanakatkul, B.F.A. Jackson, and J. Cochrane Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients Blood 91 1 1998 295 300
63. F.N. Al-Refaie, C. Hershko, A.V. Hoffbrand, M. Kosaryan, N.F. Olivieri, and P. Tondury Results of long-term deferiprone (L1) therapy: a report by the International Study Group on oral iron chelators Br J Haematol 91 1 1995 224 229
64. A.F. Collins, F.F. Fassos, S. Stobie, N. Lewis, D. Shaw, and M. Fry Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4 -one (L1) in iron-loaded patients with sickle cell disease Blood 83 8 1994 2329 2333
65. F.N. Al-Refaie, L.N. Sheppard, P. Nortey, B. Wonke, and A.V. Hoffbrand Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload Br J Haematol 89 2 1995 403 408
66. D. Matsui, J. Klein, C. Hermann, V. Grunav, R. McClelland, and D. Chung Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-1 in patients with thalassemia Clin Pharmacol Ther 50 3 1991 394 398
67. F.N. Al-Refaie, B. Wonke, A.V. Hoffbrand, D.G. Wickens, P. Nortey, and G.J. Kontoghiorges Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major Blood 80 3 1992 593 599
68. G.J. Kontoghiorghes, M.A. Aldouri, A.V. Hoffbrand, J. Barr, B. Wonke, and T. Kourouclaris Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-1 BMJ 295 6612 1987 1509 1512
69. N.F. Olivieri, G. Koren, C. Hermann, Y. Bentur, D. Chung, and J. Klein Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients Lancet 336 8726 1990 1275 1279
70. M.B. Agarwal, S.S. Gupte, C. Viswanathan, D. Vasandani, J. Ramanathan, and N. Desai Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial Br J Haematol 82 2 1992 460 466
71. B. Wonke, C. Wright, and A.V. Hoffbrand Combined therapy with deferiprone and desferrioxamine Br J Haematol 103 2 1998 361 364
72. N.F. Olivieri, G.M. Brittenham, C.E. McLaren, D.M. Templeton, R.G. Cameron, and R.A. McClelland Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major N Engl J Med 339 7 1998 417 423
73. N.F. Olivieri, G.M. Brittenham, D. Matsui, M. Berkovitch, L.M. Blendis, and R.G. Cameron Iron-chelation therapy with oral deferiprone in patients with thalassemia major N Engl J Med 332 14 1995 918 922
74. A.R. Cohen, R. Galanello, A. Piga, V. DeSanctis, and F. Tricta Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone Blood 102 5 2003 1583 1587
75. A. Ceci, P. Baiardi, M. Felisi, M.D. Cappellini, V. Carnelli, and V. DeSanctis The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients Br J Haematol 118 1 2002 330 336
76. A. Maggio, G. D'Amico, A. Morabito, M. Capra, C. Ciaccio, and P. Cianciulli Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial Blood Cells Mol Dis 28 2 2002 196 208
77. A.R. Cohen, R. Galanello, A. Piga, A. DiPalma, C. Vullo, and F. Tricta Safety profile of the oral iron chelator deferiprone: a multicentre study Br J Haematol 108 2 2000 305 312
78. R. Fischer, F. Longo, P. Nielsen, R. Engelhardt, R.C. Hider, and A. Piga Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry Br J Haematol 121 6 2003 938 948
79. P. Mazza, B. Amurri, G. Lazzari, C. Masi, G. Palazzo, and M.A. Spartera Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia Haematologica 83 6 1998 496 501
80. A. Taher, M. Sheikh-Taha, S. Koussa, A. Inati, R. Neeman, and F. Mourad Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients Eur J Haematol 67 1 2001 30 34
81. L.J. Anderson, B. Wonke, E. Prescott, S. Holden, J.M. Walker, and D.J. Pennell Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia Lancet 360 933d 2002 516 520
82. A. Piga, C. Gaglioti, E. Fogliacco, and F. Tricta Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis Haematologica 88 5 2003 489 496
83. F.N. Al-Refaie, B. Wonke, and A.V. Hoffbrand Deferiprone-associated myelotoxicity Eur J Haematol 53 5 1994 298 301
84. J. Mehta, S. Singhal, R. Revankar, A. Walvalkar, A. Chablani, and B.C. Mehta Fatal systemic lupus erythematosus in patient taking oral iron chelator L1 Lancet 337 8736 1991 298
85. A. Castriota-Scanderbeg, and M. Sacco Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone) Br J Haematol 96 2 1997 254 255
86. P. Tondury, A. Zimmerman, P. Nielsen, and A. Hirt Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients Br J Haematol 101 3 1998 413 415
87. I.R. Wanless, G. Sweeney, A.P. Dhillon, M. Guido, A. Piga, and R. Galanello Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia Blood 100 5 2002 1566 1569
88. K. Balveer, K. Pyar, and B. Wonke Combined oral and parenteral iron chelation in beta thalassaemia major Med J Malaysia 55 4 2000 493 497
89. F.H. Mourad, A.V. Hoffbrand, M. Sheikh-Taha, S. Koussa, A.I. Khoriaty, and A. Taher Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients Br J Haematol 121 1 2003 187 189
90. A. Kattamis, C. Kassou, V. Ladis, H. Berdoussi, I. Papasotiriou, and C. Kattamis Safety and efficacy of combining deferiprone and deferoxamine in iron chelation therapy in patients with thalassemia Blood 100 11 2002 120a
91. W. Breuer, M.J. Ermers, P. Pootrakul, A. Abramov, C. Hershko, and Z.I. Cabantchik Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy Blood 97 3 2001 792 798
92. R. Galanello, A. Piga, D. Alberti, M.C. Rouan, H. Bigler, and R. Sechaud Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia J Clin Pharmacol 43 6 2003 565 572
93. E. Nisbet-Brown, N.F. Olivieri, P.J. Giardina, R.W. Grady, E.J. Neufeld, and R. Sechaud Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial Lancet 361 9369 2003 1597 1602
94. A. Piga, R. Galanello, M.D. Cappellini, G.-L. Forni, G. Lupo, and J.M. Ford Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy Blood 102 11 2003 121a
95. H. Nick, P. Acklin, R. Lattmann, P. Buehlmayer, S. Hauffe, and J. Schupp Development of tridentate iron chelators: from desferrithiocin to ICL670 Curr Medic Chem 10 12 2003 1065 1076
96. A.R. Cohen, M.B. Martin, J.H. Silber, H.C. Kim, K. Ohene-Frempong, and E. Schwartz A modified transfusion program for prevention of stroke in sickle cell disease Blood 79 7 1992 1657 1661
97. H.C. Kim, N.P. Dugan, J.H. Silber, M.B. Martin, E. Schwartz, and K Ohene-Frempong Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease Blood 83 4 1994 1136 1142
98. R.D. Propper, L.N. Button, and D.G. Nathan New approaches to the transfusion management of thalassemia Blood 55 1 1980 55 60
99. B. Modell, and V. Berdoukas The clinical approach to thalassaemia 1984 Grune & Stratton London
100. S. Piomelli The management of patients with Cooley's anemia: transfusion and splenectomy Sem Hematol 32 4 1995 262 268
101. L. Corash, H. Klein, A. Deisseroth, B. Shafer, S. Rosen, and J. Beman Selective isolation of young erytrhocytes for transfusion support of thalassemia major patients Blood 57 3 1981 599 606
102. J.H. Graziano, S. Piomelli, C. Seaman, T. Wang, A.R. Cohen, and J.F. Kelleher Jr A simple technique for preparation of young red cells for transfusion from ordinary blood units Blood 59 4 1982 865 868
103. S. Piomelli, C. Seaman, J. Reibman, A. Tytun, J. Graziano, and N. Tabachnik Separation of younger red cells with improved survival in vivo: an approach to chronic transfusion therapy Proc Natl Acad Sci USA 75 7 1978 3474 3478
104. A.F. Collins, C. Gonclaves-Dias, S. Haddad, R. Talbot, R. Herst, and B.J. Tyler Comparison of a transfusion preparation of newly formed red cells and standard washed red cell transfusions in patients with homozygous beta-thalassemia Transfusion 34 6 1994 517 520
105. R.E. Marcus, B. Wonke, H.M. Bantock, M.J. Thomas, E.S. Parry, and H. Taite A prospective trial of young red cells in 48 patients with transfusion-dependent thalassaemia Br J Haematol 60 1 1985 153 159
106. A.R. Cohen, J.M. Schmidt, M.B. Martin, W. Barnsley, and E. Schwartz Clinical trial of young red cell transfusions J Pediatr 104 6 1984 865 868
107. D.F. Friedman, A.F. Jawad, M.B. Martin, K. Horiuchi, C.F. Mitchell, and A.R. Cohen Erythrocytapheresis to reduce iron loading in thalassemia Blood 102 11 2003 121a
108. V.A. Berdoukas, Y.L. Kwan, and M.L. Sansotta A study on the value of red cell exchange transfusion in transfusion dependent anaemias Clin Lab Haematol 8 3 1986 209 220